A pharmaceutical composition for use in the treatment of a disease caused by influenza virus in humans, said composition containing an effective therapeutic amount or formulation of full antibodies or antigen-binding fragments of antibodies specific to the peptide toll-like receptor type 3 sequence
(NH2)FYWNVSVHRVLGFKE(COOH), activating the antiviral host response and reducing the severity and duration of viral infections.
The present invention relates to the treatment and prevention of diseases caused by influenza viruses, including influenza viral infections. More particularly, this invention concerns novel therapeutic agents designed to modulate the antiviral host response and to reduce the severity and duration of the diseases caused by influenza viruses.
The trademark Cont®aFlu (CONTAFLU)
International application 1300446 is granted in Australia, Austria, Benelux, China, Denmark, Finland, France, Germany, India (1396099), Israel, Italy, Japan, Korea, Mexico, Norway, New Zealand, Philippines, Poland, Portugal, Russia, Singapore, Spain, Sweden, Switzerland, Tunisia, Turkey, UK, Vietnam, and USA (1396099).